Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations
Key claim: Eltrombopag, an FDA-approved thrombopoietin receptor agonist, is being evaluated as a novel therapeutic approach to improve blood counts and selectively suppress TET2-mutant clonal growth in low-risk MDS and CMML patients.
Abstract
The purpose of this study is to evaluate if a study drug called eltrombopag can improve the blood cell counts in patients with low-risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) with mutations in TET2 gene, observe changes in the TET2 gene over time, and evaluate the effectiveness of the treatment. TET2 gene is one of the most frequently mutated genes (altered parts of the DNA) in MDS and CMML.
Eltrombopag is a Food and Drug Administration (FDA) approved drug for the treatment of severe aplastic anemia and low levels of platelets in patients with persistent or chronic immune thrombocytopenia (ITP) and chronic hepatitis C. Eltrombopag is considered investigational (experimental) in this study because the FDA has not approved its use in the treatment of low-risk MDS or CMML. Eltrombopag is a drug that helps stimulate the body’s process of making more platelets (small components of blood that help with clotting) by interacting with specific parts of cells. This interaction starts a series of signals that encourage the growth and development of the cells that produce platelets. It was found that this drug could stop the growth of TET2 mutated cells.
Why this matters
Low-risk CMML and MDS/MPN overlap patients face a therapeutic gap where supportive care addresses cytopenias but does not modify clonal trajectory, while HMA-based regimens are reserved for higher-risk disease. Repurposing eltrombopag as a TET2-mutation-selective agent would be the first low-risk-specific therapy with a dual mechanism — count support plus clone-directed pressure — in a molecularly defined slice of these subtypes. If validated, it would establish a new genotype-guided treatment paradigm distinct from the HMA/BCL-2/JAK-dominated pipeline currently shaping CMML and MDS/MPN overlap care.